Home/Qbiotics/Ebru Davidson
ED

Ebru Davidson

Interim CEO and Managing Director

Qbiotics

Therapeutic Areas

Qbiotics Pipeline

DrugIndicationPhase
Tigilanol tiglateSoft tissue sarcoma, head and neck cancersPhase 2
EBC-1013Venous leg ulcers (chronic wounds)Phase 1
Antibiotic discovery programmeBacterial virulence inhibitionPreclinical